Form 8-K - Current report:
SEC Accession No. 0001193125-25-134462
Filing Date
2025-06-04
Accepted
2025-06-04 07:13:27
Documents
13
Period of Report
2025-06-04
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d944102d8k.htm   iXBRL 8-K 24699
2 EX-99.1 d944102dex991.htm EX-99.1 18989
  Complete submission text file 0001193125-25-134462.txt   168483

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA sion-20250604.xsd EX-101.SCH 2876
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE sion-20250604_lab.xml EX-101.LAB 18736
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE sion-20250604_pre.xml EX-101.PRE 11724
15 EXTRACTED XBRL INSTANCE DOCUMENT d944102d8k_htm.xml XML 3764
Mailing Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451
Business Address 21 HICKORY DRIVE, SUITE 500 WALTHAM MA 02451 617-819-2020
Sionna Therapeutics, Inc. (Filer) CIK: 0002036042 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-42504 | Film No.: 251021894
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)